skip to Main Content

February 19, 2021

February 19th, 2021

Meeting Minutes: QI Collaborative Clinical Leadership Meeting

Key points:

  • Collaborative growth: we now have 32 clinics participating!
    • 24 pediatric sites, 8 adult sites
  • Special projects
    • Data Governance Committee reviews projects that will involve de-identified patient level data per DUA
    • COVID T1D Surveillance Study: last webinar March 2021, registry open until Sept 2021
    • Smart Pen Project
    • Fear of Hypoglycemia screener being validated for real world use in QIC Adult practices, August 2021-Jan 2022.
  • Sustainability opportunities
    • RWJF Policies for Action
    • Health Forward
    • New York Community Trust. Joint application being considered in partnership with NY Collaborative PIs; NYU, Northwell, and Cornell.
  • Health equity project
    • Reducing Inequities In Diabetes Technology Device Use Among Patients With T1D
    • Medtronic supported pilot
    • Four clinical sites to pilot 10 Steps T1Dx-QI Health Equity Framework
    • Register here for the T1D Health Inequities Webinar!
  • T1DX-QI Contacts: new updated clinic contact list has been created and added to our QI Collaborative trello
  • Phase One Measures Due
  • Invoices due for 2020

Adult Measures

  • Reporting adult measures (phase one):
    • Differences among age categories and glycemic targets
    • Altering Insulin Pump Measures: keep process measure but remove increase goal
  • Phase two adult measures
    • Additions to Time in Range measure, adding Blood Measure measure
    • Removal of Bolus 3X among pump users

Next Steps:

  • Think about and send topics that are relevant that you want to discuss with other clinical leaders. It can be an informal, what is on your mind, challenges that you are navigating, bright spots, etc. We want to make some space during these calls to hear from you.
    • Alignment of QI Collaborative goals with personal development and academic responsibilities

 

POWERPOINT PRESENTATION

T1DX-QI

This Post Has 0 Comments

Leave a Reply